Although the sample size is small in this pilot study, there is a more rapid improvement in airflow through the time of disposition in the VMN group when compared to the JN group.
This suggests that there may be a clinical benefit of improved aerosol delivery with the more recently introduced VMN versus the traditional JN technology in asthma exacerbation.
Significant improvement in lung function (FVC) with an accompanied improvement in patient’s breathlessness score during COPD exacerbation with just a single 2.5mg salbutamol dose delivered with the Aerogen Ultra.
The Aerogen Solo delivered a significantly great amount of aerosol (P-values <0.05) when compared to a jet nebuliser for all positions evaluated (dry side of the humidifier and at tracheostomy tube) during spontaneously breathing and mechanical ventilation in tracheostomy patients.
A performance improvement plan including the use of noninvasive methods of ventilatory support and efficient advanced aerosol techniques using the Aerogen Solo had a positive impact on clinical outcomes, as well as staff and patient satisfaction
Cost per patient was reduced to $46 from $191 after transition from MDI to the Aeroneb Solo during ventilation. Potential (105 hospitals) implementation could lead to annual savings from $870,000 - $1,740,000
Aerosol therapy during mechanical ventilation is used by more than 95 % of intensivists mainly to deliver bronchodilators and steroids. A breakdown of the drugs and nebulisers used worldwide is presented.
The Aeroneb Pro and Aeroneb Solo have a greater emitted/inhaled dose compared to a Jet Nebulizer in a simulated adult model of non-invasive ventilation. Dose increased with both nebulizers positioned on the patient side of the exhalation/leak port
In vitro model of CPAP and non-invasive ventilation demonstrated increased inhaled mass with the NIVO compared to a small volume nebulizer. The NIVO treatment time was also reduced and minimal residual volume was observed
A urinary pharmacokinetic method of drug excretion was used to show the performance of the Aeroneb Pro and a jet nebuliser during non-invasive ventilation with COPD patients.
The Aeroneb Pro was deemed the more efficient nebuliser.
Inhaled dose was greater for the Aeroneb Pro than the jet nebulizer when positioned both patient side and ventilator side of the leak port. The respirable dose is significantly higher when the nebulizer is positioned patient side of the leak port